Caution! The site can't guarantee, that text has age permission. The site is not recommended, if you are less than 18 years old.
The site shows example sentences for English words. How the word or phrase could be used in a sentence?
" ... The Company's HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Genvoya is an oral formulation dosed once a day for the treatment of HIV-1 infection in adults. Genvoya is a fixed-dose combination of its antiretroviral medicines, Vitekta (elvitegravir), Tybost (cobicistat), Emtriva (emtricitabine) and tenofovir alafenamide (TAF). Stribild is an oral formulation dosed once a day for the treatment of HIV-1 infection in treatment-naive adults. Stribild is a fixed-dose combination of its antiretroviral medications, Vitekta, Tybost, Viread and Emtriva. Complera/Eviplera is an oral formulation dosed once a day for the treatment of HIV-1 infection in adults. Complera/Eviplera is a fixed-dose combination of its antiretroviral medications, Viread and Emtriva, and Janssen's non-nucleoside reverse transcriptase inhibitor, Edurant (rilpivirine). Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Atripla is a fixed-dose combination of the Company's antiretroviral medications, Viread and Emtriva, and Bristol-Myers Squibb Company's (BMS's) non-nucleoside reverse transcriptase inhibitor, Sustiva (efavirenz). Truvada (emtricitabine and tenofovir disoproxil fumarate) is an oral formulation dosed once a day as part of combination therapy to treat HIV infection in adults. It is a fixed-dose combination of its antiretroviral medications, Viread and Emtriva. Viread is an oral formulation of a nucleotide analog reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in patients of over two years of age and older. The European Commission approved the use of Viread in combination with other antiretroviral agents for the treatment of HIV-1 infected adolescent patients aged 2 to less than 18 years with nucleoside reverse transcriptase inhibitor resistance or toxicities precluding the use of first-line pediatric agents. Emtriva is an oral formulation of a nucleoside analog reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. In the United States and Europe, Emtriva is also available as an oral solution approved as part of combination therapy to treat HIV infection in children. Tybost is a pharmacokinetic enhancer dosed once a day that boosts blood levels of certain HIV medicines. Tybost is indicated as a boosting agent for the HIV protease inhibitors atazanavir and darunavir as part of antiretroviral combination therapy in adults with HIV-1 infection. Vitekta is an oral formulation of an integrase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults without known mutations associated with resistance to elvitegravir, the active ingredient of Vitekta. Vitekta is indicated for use as part of HIV treatment regimens that include a ritonavir-boosted protease inhibitor. In addition, the Company is investigating over two additional TAF-based single tablet regimens; TAF, emtricitabine and GS-9883, its integrase inhibitor, which is in Phase III clinical studies, and TAF, emtricitabine, cobicistat and Janssen's darunavir (D/C/F/TAF), which is being developed and commercialized by Janssen. ... "